NorthCrest Asset Manangement’s United Therapeutics UTHR Stock Holding History

NorthCrest Asset Manangement’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.11M	Buy	5,628 +23	+0.4%	+$13K	0.08%	186
2026 Q1	$3.17M	Sell	5,605 -1,932	-26%	-$962K	0.1%	172
2025 Q4	$3.69M	Buy	7,537 +1,843	+32%	+$858K	0.08%	174
2025 Q3	$2.6M	Buy	5,694 +262	+5%	+$88.1K	0.06%	199
2025 Q2	$1.6M	Buy	5,432 +97	+2%	+$29K	0.04%	240
2025 Q1	$1.64M	Sell	5,335 -263	-5%	-$90.1K	0.05%	230
2024 Q4	$1.98M	Buy	5,598 +84	+2%	+$30.9K	0.06%	205
2024 Q3	$1.98M	Buy	5,514 +238	+5%	+$80.4K	0.06%	207
2024 Q2	$1.68M	Buy	5,276 +1	+0%	+$265	0.06%	214
2024 Q1	$1.21M	Sell	5,275 -60	-1%	-$13.5K	0.04%	254
2023 Q4	$1.17M	Hold	5,335	–	–	0.04%	245
2023 Q3	$1.21M	Hold	5,335	–	–	0.05%	235
2023 Q2	$1.18M	Hold	5,335	–	–	0.05%	243
2023 Q1	$1.19M	Hold	5,335	–	–	0.05%	235
2022 Q4	$1.48M	Hold	5,335	–	–	0.08%	142
2022 Q3	$1.12M	Hold	5,335	–	–	0.06%	195
2022 Q2	$1.26M	Hold	5,335	–	–	0.06%	185
2022 Q1	$957K	Buy	5,335 +80	+2%	+$15.2K	0.05%	206
2021 Q4	$1.14M	Buy	+5,255	New	+$1.03M	0.06%	205

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

NorthCrest Asset Manangement's UTHR Position: Q2 2026 in Review

NorthCrest Asset Manangement increased its United Therapeutics (UTHR) stake by 0.41% in Q2 2026, buying an estimated $13K and bringing the position to 5,628 shares worth $3.11M. The position accounts for 0.08% of the portfolio, ranked #186.

NorthCrest Asset Manangement first reported a position in UTHR in Q4 2021 and has held it in 19 quarters since. The position peaked at $3.69M in Q4 2025. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

NorthCrest Asset Manangement held 5,628 shares of United Therapeutics worth $3.11M as of Q2 2026.
NorthCrest Asset Manangement bought 23 United Therapeutics shares in Q2 2026, an estimated $13K.
United Therapeutics made up 0.08% of NorthCrest Asset Manangement's portfolio in Q2 2026, its #186 holding.
NorthCrest Asset Manangement first reported a position in United Therapeutics in Q4 2021 and has held it in 19 quarters since.
NorthCrest Asset Manangement's United Therapeutics position peaked at $3.69M in Q4 2025.
880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on NorthCrest Asset Manangement's 13F filing for Q2 2026, filed 15 Jul 2026.